Compare, Analyse Fresenius Kabi Onco. with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs MYLAN (US) - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

MYLAN (US)
   Change

Mylan is one of the worlds leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industrys broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 FRESENIUS KABI ONCO.   MYLAN
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
MYLAN
Dec-18
FRESENIUS KABI ONCO./
MYLAN
5-Yr Chart
Click to enlarge
High Rs1763,512-   
Low Rs791,933-   
Sales per share (Unadj.) Rs37.71,616.0-  
Earnings per share (Unadj.) Rs5.143.9-  
Cash flow per share (Unadj.) Rs6.7346.5-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.51,748.2-  
Shares outstanding (eoy) m158.23514.50-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.41.7 200.4%   
Avg P/E ratio x25.062.0 40.3%  
P/CF ratio (eoy) x18.97.9 240.9%  
Price / Book Value ratio x3.01.6 192.1%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,1351,400,717 1.4%   
No. of employees `0001.235.0 3.3%   
Total wages/salary Rs m7030-   
Avg. sales/employee Rs Th5,176.223,755.1 21.8%   
Avg. wages/employee Rs Th610.40-   
Avg. net profit/employee Rs Th699.6645.0 108.5%   
INCOME DATA
Net Sales Rs m5,963831,427 0.7%  
Other income Rs m180-   
Total revenues Rs m5,981831,427 0.7%   
Gross profit Rs m1,430215,142 0.7%  
Depreciation Rs m258155,676 0.2%   
Interest Rs m-2639,989 -0.1%   
Profit before tax Rs m1,21619,478 6.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342-3,099 -11.0%   
Profit after tax Rs m80622,577 3.6%  
Gross profit margin %24.025.9 92.7%  
Effective tax rate %28.1-15.9 -176.9%   
Net profit margin %13.52.7 497.7%  
BALANCE SHEET DATA
Current assets Rs m5,102464,268 1.1%   
Current liabilities Rs m2,385338,503 0.7%   
Net working cap to sales %45.615.1 301.1%  
Current ratio x2.11.4 155.9%  
Inventory Days Days15084 179.5%  
Debtors Days Days11393 121.4%  
Net fixed assets Rs m5,148161,283 3.2%   
Share capital Rs m158443 35.7%   
"Free" reserves Rs m6,5560-   
Net worth Rs m6,732899,452 0.7%   
Long term debt Rs m952970,797 0.1%   
Total assets Rs m10,3882,412,680 0.4%  
Interest coverage x-45.81.5 -3,078.3%   
Debt to equity ratio x0.11.1 13.1%  
Sales to assets ratio x0.60.3 166.6%   
Return on assets %7.52.6 289.5%  
Return on equity %12.02.5 476.9%  
Return on capital %14.63.2 459.3%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Net fx Rs m3,5250-   
CASH FLOW
From Operations Rs m1,274172,771 0.7%  
From Investments Rs m-1,204-89,303 1.3%  
From Financial Activity Rs m-196-80,487 0.2%  
Net Cashflow Rs m-1261,431 -8.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 73.78 Rs / USD

Compare FRESENIUS KABI ONCO. With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare FRESENIUS KABI ONCO. With: DISHMAN PHARMA  DR. DATSONS LABS  TORRENT PHARMA  AUROBINDO PHARMA  GLENMARK PHARMA  



Today's Market

Sensex Opens Flat; Tata Steel Jumps 4% Post Q4 Results(09:30 am)

Asian share markets rose in early trade today after data released overnight showed the US services sector added hundreds of thousands of jobs last month.

Related Views On News

Why Did Alembic Pharma Shares Fall Today? (Views On News)

May 5, 2021

Covid-led supply disruptions of API fuel Alembic Pharma's global prospects.

More Views on News

Most Popular

Power Grid's InvIT IPO: Key Points to Consider (Company Info)

Apr 23, 2021

In this article, we discuss the key reasons why the stock of Power Grid was in focus today.

Time to Buy Smallcaps? (Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners (Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

This Fund Manager Has Taken the World by Storm. Will You Invest With Her? (Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Learn: How to Potentially Accumulate Rs 7 Crore in Wealth Over the Long-term
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

FEATURED VIDEOS

The 'Big' Money is in this 'Small' Detail

Stability, Quality or Green Stocks for 2021?

Market Crash: Picture Abhi Baaki Hai?

It's a Great Time to Buy Gold

More Featured Videos

MARKET STATS